Atherosclerotic Plaque Biomarkers: Beyond the Horizon of the Vulnerable Plaque by W. van Lammeren, Guus et al.
22  Current Cardiology Reviews, 2011, 7, 22-27
     1573-403X/11 $58.00+.00  © 2011 Bentham Science Publishers Ltd.
Atherosclerotic Plaque Biomarkers: Beyond the Horizon of the Vulnerable 
Plaque 
Guus W. van Lammeren
1,2, Frans L. Moll
2, Gert Jan De Borst
2, Dominique P.V. de Kleijn
1,
Jean-Paul P.M. de Vries
3 and Gerard Pasterkamp
1,*
1Experimental Cardiology Laboratory, University Medical Center Utrecht, The Netherlands, 
2Department of Vascular 
Surgery, University Medical Center Utrecht, The Netherlands, 
3Department of Vascular Surgery, St Antonius Hospital 
Nieuwegein, The Netherlands 
Abstract: Cardiovascular disease (CVD) is the number one cause of death globally, and the majority of CVD is caused by 
atherosclerosis. Atherosclerosis is a systemic inflammatory disease that leads to myocardial infarction, stroke and lower 
limb ischemia. Pathological studies have given insight to development of atherosclerosis and the importance of local 
plaque vulnerability, leading to thrombus formation and cardiovascular events. Due to the burden of cardiovascular dis-
ease, identification of patients at risk for cardiovascular events and treatment stratification is needed. The predictive power
of classical risk factors is limited, especially in patients with manifest atherosclerosis. Imaging modalities have focused on 
the characteristics of the vulnerable plaque. However, it has become evident that not all so-called vulnerable plaques lead 
to rupture and subsequent thrombosis. The latter obviously limits the positive predictive value for imaging assessment of 
plaques and patients at risk. Serum biomarkers have also been studied extensively, but have very limited application in a 
clinical setting for risk stratification. In line with the important relation between vulnerable plaques and cardiovascular 
events, plaque biomarker studies have been initiated. These longitudinal studies are based on the concept, that a vulner-
able plaque contains predictive information for future cardiovascular events, also in other territories of the vascular tree. 
Results look promising and plaque markers can be used to develop imaging modalities to identify patients at risk, or to 
monitor treatment effect. Plaque biomarker studies do not challenge the definition of the vulnerable plaque, but use its 
concept in favor of prediction improvement for vascular patients.  
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INTRODUCTION 
  Cardiovascular disease (CVD) is the major cause of mor-
bidity and mortality worldwide and is predominantly caused 
by atherosclerosis [1]. Atherosclerosis is an inflammatory 
process resulting in local plaque deposition in the vessel wall 
of arteries, leading to luminal narrowing and decreased tissue 
perfusion. Although atherosclerotic plaque development is a 
local process in the vessel wall that can give rise to symp-
toms in one specific area, it is also a systemic condition with 
simultaneous plaque formation in different areas of the vas-
cular tree [2, 3]. Patients can present with myocardial ische-
mia if coronary arteries are affected; with cerebrovascular 
events if carotid arteries are affected or with lower limb 
ischemia if peripheral arteries are involved. The systemic 
character of atherosclerosis is one of the key, and disadvan-
tageous properties of the disease. Classical risk factors for 
development of CVD have been identified from population 
based studies and include age, gender, cigarette smoking, 
high blood pressure, elevated cholesterol levels, diabetes 
mellitus, obesity and familial history of coronary heart dis-
ease [4-8]. 
*Address correspondence to this author at the Experimental Cardiology 
Laboratory, Department of Cardiology, University Medical Center Utrecht 
Heidelberglaan 100, Room G02.523, 3584 CX Utrecht The Netherlands; 
Tel: (+31) 88 755 7155; Fax: (+31) 30 252 2693;  
E-mail: g.pasterkamp@umcutrecht.nl 
DEVELOPMENT OF ATHEROSCLEROSIS 
  The important role of lipids in the development of athe-
rosclerosis was described by Ross in 1976 [9]. In addition to 
hyperlipidemia, the role of inflammation in atherosclerotic 
plaque formation and progression is yet undisputable [10, 
11]. In short, initiation of atherosclerosis starts with an in-
creased permeability of the arterial endothelium, which fa-
cilitates migration of cholesterol-filled low density lipopro-
tein (LDL) particles into the vessel wall. After migration into 
the intimal layer, LDL particles become oxidized. This re-
sults in an inflammatory response and the attraction of 
monocytes to the lesion. Monocytes differentiate into 
macrophages and take up the oxidized lipoproteins and turn 
into foam cells. Foam cells eventually precipitate in the ves-
sel wall causing a fatty streak, which further stimulates the 
inflammatory process. Further attraction of macrophages is 
promoted, together with migration of proliferating smooth 
muscle cells (SMC) from the medial into the intimal layer of 
the arterial wall. SMCs produce collagen which results in 
formation of a fibrous cap overlying the atheroma; and cov-
ering the atherosclerotic plaque.  
THE VULNERABLE PLAQUE 
  Postmortem studies revealed that acute myocardial in-
farction and coronary death were associated with coronary 
plaque disruption caused by fibrous cap rupture, superim-
posed thrombus formation and coronary occlusion. Thinning Atherosclerotic Plaque Biomarkers  Current Cardiology Reviews, 2011, Vol. 7, No. 1    23
of the fibrous cap was shown to be caused by a decreased 
collagen production as a result of decreased SMC content, or 
degradation by matrix metalloproteinases (MMPs) excreted 
by macrophages [12]. This led to the description of the entity 
vulnerable plaques by Davies in 1996, who stated that 
plaques with large lipid cores, low SMC content, high 
macrophage content and a thin fibrous cap are rupture prone 
and therefore vulnerable [13]. Based on these principles and 
plaques found in patients who died from sudden coronary 
death, a morphological classification and scoring system for 
atherosclerotic lesions was established by Virmani et al.
[14]. In 2003, the importance of intraplaque hemorrhage for 
progression of atheroma was elucidated by Kolodgie et al.
[15]. The researchers showed that intraplaque hemorrhage 
contributes to deposition of free cholesterol, macrophage 
infiltration and enlargement of the necrotic core which in-
creases the risk of plaque destabilization. One of the causes 
for intraplaque bleeding was hypothesized to be related to 
leaky microvessels inside the atherosclerotic plaque. Intra-
plaque microvessels result from angiogenesis, most likely 
under influence of hypoxic and inflammatory stimuli [16]. 
The leaky vessel hypothesis was recently extended by 
Sluimer et al. who showed that increased microvessel den-
sity was associated with an unstable plaque morphology and 
rupture prone plaques [17]. Compromised integrity of the 
endothelium of microvessels was held responsible for leak-
age of red blood cells into the atherosclerotic plaque, giving 
rise to intraplaque hemorrhage. A schematic illustration of 
the current view on stable and unstable atherosclerotic 
plaques is depicted in Fig. (1). The vulnerable plaque con-
cept also applies for carotid plaques. Vulnerable plaques 
were observed in symptomatic patients, who suffered from 
cerebrovascular events like stroke and transient ischemic 
attack (TIA), as opposed to asymptomatic patients, who had 
relatively stable plaques [18]. These findings confirmed that 
local plaque processes are associated with local plaque sta-
bility and the occurrence of an event in the respective area of 
the vascular tree. 
THE SEARCH FOR BIOMARKERS TO DETECT THE 
VULNERABLE PATIENT 
  Based on classical cardiovascular risk factors, the 
Framingham Heart registry identified clinical predictors for 
adverse cardiovascular outcome in the entire population [19]. 
Within the domain of patients with vascular disease, classical 
risk factors have limited discriminative values, because most 
patients have a certain amount of the risk factors. Due to the 
growing evidence of the association of vulnerable plaques 
with cardiovascular events, a consensus statement was pub-
lished in 2003 by Naghavi et al. to encourage translational 
research for the identification and treatment of vulnerable 
patients, based on the concept of the vulnerable plaque [20]. 
Taking the concept of the vulnerable plaque as a starting 
point, a more systemic approach was considered to identify 
patients at risk for cardiovascular death. This resulted in 
numerous studies in search of so-called biomarkers. A bio-
marker is defined as a characteristic that is objectively meas-
ured and evaluated as an indicator of normal biologic proc-
esses, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention [21]. Due to the pivotal role of lipids 
and inflammation in development of atherosclerosis, choles-
terol and inflammatory markers were thoroughly studied. 
The predictive value of cholesterol markers for cardiovascu-
lar events is limited, because more than half of all vascular 
events occur in individuals with normal cholesterol levels 
[22]. Lipoprotein-associated phospholipase A2 (Lp-PLA2) 
has been described as a potential marker for CVD and mor-
tality [23]. However, Lp-PLA2 levels drop significantly after 
Fig. (1). Schematic overview of a stable atherosclerotic plaque (left) and an unstable atherosclerotic plaque (right). 24 Current Cardiology Reviews, 2011, Vol. 7, No. 1  van Lammeren et al. 
stroke and myocardial infarction [24]. As a result of this 
unstable marker property, the use of Lp-PLA2 might be less 
reliable for long-term risk stratification shortly after primary 
events. 
  The inflammatory biomarker c-reactive protein (CRP) 
has been reported to be a predictive marker for cardiovascu-
lar events among healthy individuals; and that it adds prog-
nostic information to the Framingham risk score [22]. The 
JUPITER trial investigators concluded that high-sensitivity 
CRP and LDL levels in healthy individuals can be lowered 
by prophylactic treatment with statins, which also resulted in 
a significant decrease of cardiovascular events, even in the 
absence of hyperlipidemia [25, 26]. This indicates that CRP 
can be used to identify patients at risk; and that CRP and 
LDL can be used as biomarkers for treatment effect. Never-
theless, an inflammatory marker like CRP has its limitations, 
since it is not specific for atherosclerosis and cardiovascular 
events. Serum CRP levels dramatically increase in case of 
any infection or tissue damage caused by trauma [27] and it 
is therefore controversial to start aggressive treatment solely 
based on elevated CRP levels. Recent analysis of inflamma-
tory markers, including hs-CRP, interleukins 6, 10 and 18, 
soluble CD40 ligand, P- and E-selectin, NT-proBNP, fi-
brinogen and cystatin C, in patients with acute coronary 
syndrome showed that all markers by themselves offer only 
limited incremental information to clinical risk scores [28]. 
However, a combination of fibrinogen and NT-proBNP 
contained predictive information in addition to clinical pa-
rameters. 
  Besides serum marker studies, non invasive imaging 
modalities have been studied extensively. Imaging can be 
considered useful for screening for vulnerable plaques and 
thereby identifying high risk patients, but also to monitor the 
stabilizing effect of treatment on local plaque composition. 
Imaging of plaque inflammation has been extensively stud-
ied with positron emission tomography (PET), and has 
shown its potential since 2002 [29]. Imaging of proteolytic 
enzymes such as MMPs is of interest, since these proteases 
are involved in degradation of the fibrous cap of the plaque, 
but are also predictive for future events [30, 31]. Recently it 
was shown, that labeled MMP-2 and MMP-9 can be imaged 
in human carotid plaques, but in an ex vivo situation [32]. In 
spite of ongoing improvements for plaque imaging, also 
limitations are present. Not all vulnerable plaques, also 
called thin fibrous cap atheroma (TFCA) are likely to pro-
gress to rupture and cause cardiovascular events [33]. This 
limits the positive predictive value of plaque imaging for 
cardiovascular events and identifying the patient at risk. 
Consequently, a clinical decision for invasive treatment of a 
TFCA lesion detected with imaging, cannot be made on 
these bases. It is therefore important to further define other 
markers of instability and indicators plaque rupture. Besides 
Fig. (2). Concept of pathological studies and longitudinal translational biobank studies with the atherosclerotic plaque as a starting point. 
In blue, the design of postmortem and histopathological studies allowing crossectional research to investigate the association of plaque type 
with the initial event. In green the overlap between crossectional and prospective biobank stusdies. In yellow the unique Athero-Express 
study with a longitudinal design, with the ability to investigate the association of local plaque characteristics with systemic cardiovascular 
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limitations in positive predictive power, also technical im-
provements for imaging modalities like PET scans are war-
ranted, especially for the contrast difference between the 
lesion and surrounding background (target-to-background 
ratio) and limited spatial resolution (partial volume effect) 
[34]. Secondly, the use of radioactive material and high costs 
of a PET scan are clearly limitations of this diagnostic tool. 
  Combining the limitations of serum markers and imaging 
studies, it is clear that there is a need for more specific and 
sensitive predictors for primary cardiovascular events, but 
also for secondary events in vascular patients at risk. Based 
on these needs and the central role of the vulnerable plaque 
in the occurrence of (cardio)vascular events, the Athero-
Express study was designed [35]. The study design is based 
on local plaque information and the fact that atherosclerosis 
is a systemic condition. Atherosclerotic plaque formation 
occurs throughout all large arteries in the human body, 
which might imply that local plaque properties from one 
plaque in the vascular tree might be extrapolated to other 
atherosclerotic lesions at a distant location. These specific 
properties could reveal information regarding the stability of 
not just the local plaque, but the stability of the entire athero-
sclerotic process within an individual. In Athero-Express, 
human atherosclerotic plaques are harvested during carotid 
and femoral endarterectomy. Plaques are analyzed histologi-
cally and proteins are isolated to measure inflammatory 
interleukins, MMPs and other inflammatory markers. All 
patients are prospectively followed for three years after vas-
cular surgery and endpoints are registered. The Athero-
Express study design facilitates research that relates plaque 
properties to cardiovascular events during follow up of vas-
cular patients (Fig. 2).  
RESULTS FROM LONGITUDINAL PLAQUE   
BIOMARKER STUDIES 
  The carotid plaque contains valuable information for 
follow up after vascular surgery. Hellings et al. showed that 
local plaque characteristics are associated with restenosis at 
the site of carotid endarterectomy after 1 year [36]. Endarter-
ectomy of lipid-rich, inflammatory plaques was associated 
with reduced risk of restenosis compared to stable, fibrous 
plaques, independent from clinical characteristics. 
 Recently  Hellings  et al. concluded that carotid plaque 
composition also contains predictive information for future 
cardiovascular events elsewhere in the vascular system, 
independent from established risk factors and medication use 
[37]. Patients undergoing carotid endarterectomy, with a 
local plaque containing intraplaque hemorrhage or marked 
intraplaque microvessel formation demonstrated an increased 
risk of secondary cardiovascular events with Hazard Ratios 
of 1.7 [1.2-2.5] and HR=1.4 [1.1-1.9], respectively. Other 
histological parameters like macrophage infiltration large 
lipid core, calcifications, collagen and smooth muscle cell 
infiltration were not associated with secondary events.  
  On protein level, De Kleijn et al. demonstrated that ca-
rotid plaque osteopontin (OPN) level is a predictor of car-
diovascular events after carotid endarterectomy [38]. Patients 
with plaque OPN levels in the upper quartile had a nearly 4-
fold risk for development of cardiovascular events compared 
with patients with OPN levels in the lowest quartile (adjusted 
HR = 3.5 [2.0-5.9]).  
LIMITATIONS AND FUTURE PERSPECTIVES 
  Plaque biobank studies with a longitudinal design, focus-
ing on predictive plaque biomarkers clearly do not challenge 
the definition of the vulnerable plaque, but use information 
gathered from pathological studies for prediction of cardio-
vascular events in a more systemic manner as opposed to 
pathological studies focusing on local plaque characteristics 
and local outcome. In addition, local plaque biomarkers that 
are predictive for future events, can give rise to the use of 
imaging techniques to identify and monitor patients at risk. 
Due to the important role of microvessels and intraplaque 
hemorrhage for development of vulnerable plaques, but also 
the predictive value for future events, imaging modalities for 
these plaque characteristics are of great interest [39]. A pro-
spective MRI study of carotid plaques showed that intra-
plaque hemorrhage at baseline was associated with plaque 
progression and increasing lipid core volume over an 18 
month period [40]. Carotid plaque hemorrhage detected on 
MRI in symptomatic patients was associated with emboliza-
tion during carotid endarterectomy, which might result in a 
higher periprocedural risk, but this has to be confirmed in 
larger studies [41]. Also in patients with only moderate ca-
rotid stenosis (30-69%), MRI detected intraplaque hemor-
rhage was associated with ipsilateral ischemic events during 
an 28 month follow up period [42]. But also this study in-
cluded only a limited amount of patients, therefore larger 
series will have to be obtained. Also the presence of intra-
plaque hemorrhage in asymptomatic patients and the associa-
tion with ipsilateral ischemic events will have to be studied. 
  Plaque biobank studies also have certain limitations. 
Endarterectomy is an invasive surgical procedure. Carotid or 
femoral plaque analysis is therefore limited to patients who 
undergo vascular surgery, which clearly limits the domain of 
patients suitable for risk assessment. Predictive plaque bio-
markers therefore also require external validation and inves-
tigation of the predictive power in other populations. Never-
theless, findings from plaque biomarker research can be used 
for future imaging techniques as stated above.  
  Furthermore the plaque analysis takes place at one time 
point, while it is known that atherosclerotic plaque composi-
tion changes over time. Peeters et al. showed that carotid 
atherosclerotic plaques stabilize over time after stroke [43]. 
Plaques from patients operated more than 30 days after the 
cerebrovascular event contained significantly less macro-
phages and interleukin 8 and 6. For the interpretation of 
plaque biomarkers, this time period has to be taken into 
account.  
CONCLUSION 
  Atherosclerotic plaque biomarker studies show great 
potential. Future research for validation and application in 
imaging techniques is warranted. Plaque biomarker studies 
do not challenge the definition of the vulnerable plaque, but 
use its concept in favor of prediction improvement for vascu-
lar patients. 26    Current Cardiology Reviews, 2011, Vol. 7, No. 1  van Lammeren et al. 
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